Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026)
Whitehawk Therapeutics' (WHWK) quarterly Return on Capital Employed came in at 95.88% in Q1 2026, down 5073.0% year-on-year from 1.93% in Q1 2025, and down 21.03% on a QoQ basis from 79.22% in Q4 2025.
Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 16 years of Return on Capital Employed data on file, last reported at 95.88% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 5073.0% year-over-year to 95.88% in Q1 2026; TTM through Mar 2026 was 95.88%, a 5073.0% decrease from a year earlier, with the FY2025 full-year figure at 119.1%, down 3907.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 95.88%, down from 79.22% in the prior quarter.
- Over the last five years, Return on Capital Employed for WHWK reached as high as 36.8% in Q4 2022 and fell as low as 110.71% in Q4 2024.
- Historically, Return on Capital Employed has averaged 69.23% across 5 years, with a median of 66.11% in 2025.
- Across the five-year window, Return on Capital Employed slumped 12641 bps in 2022 and jumped 6501 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 36.8% in 2022, then sank by 78 bps to 65.6% in 2023, then tumbled by 69 bps to 110.71% in 2024, then gained by 28 bps to 79.22% in 2025, then dropped by 21 bps to 95.88% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 95.88% in Q1 2026, 79.22% in Q4 2025, and 66.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Whitehawk Therapeutics | 34.18 Mn | 34.18 Mn | - | -95.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.88% |
| Dec 31, 2025 | -79.22% |
| Sep 30, 2025 | -66.11% |
| Jun 30, 2025 | -51.51% |
| Mar 31, 2025 | -45.15% |
| Dec 31, 2024 | -110.71% |
| Sep 30, 2024 | -85.07% |
| Jun 30, 2024 | -83.92% |
| Mar 31, 2024 | -73.25% |
| Dec 31, 2023 | -65.60% |
| Sep 30, 2023 | -55.79% |
| Jun 30, 2023 | -45.20% |
| Mar 31, 2023 | -41.14% |
| Dec 31, 2022 | -36.80% |
| Sep 30, 2022 | -44.02% |
| Jun 30, 2022 | -110.21% |
| Mar 31, 2022 | -87.26% |
| Dec 31, 2021 | -75.11% |
| Sep 30, 2021 | -94.91% |
| Jun 30, 2021 | -5.99% |